Biosimilar Antibody-Drug Conjugates? Pfizer Isn’t Banking On It
‘The Regulatory Path Has To Be Determined. It Doesn’t Exist Today’
Pfizer’s $43bn agreement to acquire Seagen would layer its portfolio and pipeline with vastly complex antibody-drug conjugates – a class of drug that both parties feel might be almost immune to biosimilar competition.
You may also be interested in...
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023
At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).
Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval
Samsung Bioepis responded to Generics Bulletin enquiries following its EU-wide approval for a biosimilar to AstraZeneca’s Soliris.